TB Screening for Healthcare Workers: Baseline, Annual Testing, and IGRA vs. TST

If you still line every employee up for a PPD each spring, your program is running on rules CDC retired in 2019. That is the headline for TB screening for healthcare workers, and it surprises a lot of occupational-health nurses who trained under the old 2005 guidelines: routine annual TB testing of healthcare personnel is no longer recommended in the United States.

The change came from the National Tuberculosis Controllers Association and CDC, published in MMWR on May 17, 2019 (MMWR 2019;68(19):439-443). Those recommendations updated the 2005 CDC guidelines and remain the operative federal guidance today. The model shifted from "test everyone every year" to a tighter, risk-based approach: solid screening at hire, then education and symptom checks instead of a needle in every arm each January.

What new hires need: baseline TB screening

Every new healthcare worker still gets screened before they start. The 2019 recommendations lay out four components for that baseline TB screening (preplacement) visit (MMWR 2019):

1. An individual TB risk assessment. Ask about the things that raise a person's risk — time spent in a country with high TB incidence, prior contact with someone who had infectious TB, and immunocompromising conditions. This isn't a formality; it drives how you interpret the test.
2. A symptom evaluation. Cough lasting three weeks or more, fever, night sweats, unexplained weight loss.
3. A TB test — IGRA or TST — for anyone without documented prior TB disease or latent TB infection (LTBI). If someone already has a documented history, you don't re-test; you confirm the record and move on.
4. For lower-risk personnel, a confirmatory second test if the first is positive. More on that below, because it's the step people skip.

For a lower-risk hire whose first test comes back positive, CDC recommends a second, confirmatory test. The person is considered to have TB infection only when both results are positive, and only then do you move to a chest x-ray and full symptom workup (CDC MMWR mm6819a3). One positive on a low-risk employee is not a diagnosis — it's a prompt to confirm before you send someone down the LTBI-treatment path.

Is annual TB testing still required?

Short answer: no, not routinely. The 2019 recommendations are explicit — in the absence of known exposure or evidence of ongoing transmission, U.S. healthcare personnel without LTBI should not undergo routine serial screening or testing at any interval after baseline, annual included (MMWR 2019).

What replaced the annual test is not nothing. Two things stepped in:

• Annual TB education for all healthcare personnel — a yearly touchpoint on TB risk factors, signs and symptoms, and what to do if they develop them.
• Annual symptom screening, but only for personnel with untreated LTBI. If someone carries latent infection and hasn't been treated, you check them yearly for symptoms of progression to active disease.

The rationale is straightforward: TB has gotten much rarer here. CDC pointed to a 73% decline in reported U.S. TB, from 10.4 per 100,000 in 1991 to 2.8 per 100,000 in 2017 (MMWR 2019). At that prevalence, annual testing of a low-risk workforce generates far more false positives and unnecessary follow-up than real cases caught.

One caveat you cannot ignore. CDC says annual testing is "not routinely recommended" — not "prohibited." State and local TB control programs, and some facility or accreditation requirements, may still impose their own testing cadence. Before you rewrite your policy, call your state TB control program and confirm what your jurisdiction requires. Plenty of facilities have dropped annual testing on the strength of the CDC change only to discover their state licensure rules hadn't moved.

IGRA vs. TST: which test, and why it matters

When you do test, you have two categories of tool. Understanding the IGRA vs. TST trade-offs will save you re-tests and false alarms.

The tuberculin skin test (TST, or Mantoux) is the intradermal PPD you already know. It requires two visits — one to place the test and one to read the induration 48 to 72 hours later (CDC MMWR RR-5, 2010). Miss the reading window and you start over. It's also prone to false positives in people who received BCG vaccine or who've had exposure to nontuberculous mycobacteria.

Interferon-gamma release assays (IGRAs) are blood tests — a single draw at one visit, no return trip. There are two FDA-approved products: QuantiFERON-TB Gold from QIAGEN and T-SPOT.TB from Oxford Immunotec (CDC MMWR RR-5, 2010). The QuantiFERON TB test is the one most occupational-health clinics encounter. IGRAs use the antigens ESAT-6 and CFP-10, which are absent from BCG strains and from most nontuberculous mycobacteria — so a prior BCG vaccination doesn't confound the result (CDC MMWR RR-5, 2010).

CDC doesn't mandate one over the other. In practice, IGRA earns its place in two situations: with BCG-vaccinated staff, where it avoids the false-positive headache, and anywhere a 48-to-72-hour return visit is hard to guarantee — traveling nurses, per-diem hires, high-turnover units. For a mostly U.S.-trained, low-turnover workforce where cost matters, TST is still perfectly defensible.

The 2019 CDC TB guidelines, in one place

If you want the CDC 2019 TB guidelines summarized for a policy document, here's the spine:

• Baseline (preplacement) screening for all HCP: risk assessment, symptom evaluation, and an IGRA or TST for those without prior documented TB disease or LTBI.
• No routine serial (annual) testing absent known exposure or ongoing transmission.
• Annual TB education for all HCP.
• Annual symptom screening for HCP with untreated LTBI.
• A confirmatory second test for lower-risk HCP whose first test is positive.
• Treatment for all HCP diagnosed with untreated LTBI, unless contraindicated (MMWR 2019).

That treatment point is the quiet win of the whole update — the effort saved by dropping annual testing is meant to redirect toward actually treating the latent infections you find. TB treatment regimens evolve, so don't hardcode a regimen into your policy; point clinicians to the current CDC TB treatment pages for the currently preferred options.

What about after a known exposure?

Ending routine serial testing doesn't touch post-exposure testing. When there's a documented exposure to someone with infectious TB, or evidence of ongoing transmission in your facility, serial testing still applies. Post-exposure follow-up typically involves a baseline test around the time of exposure and repeat testing after an incubation window; run it per your health department's contact-investigation protocol rather than a fixed calendar. The 2019 change narrowed routine testing, not exposure response.

The OSHA and recordkeeping angle

There is no dedicated OSHA tuberculosis standard. OSHA enforces TB protection through general standards: the Respiratory Protection standard (29 CFR 1910.134), Recordkeeping (29 CFR 1904.11), Access to Employee Exposure and Medical Records (29 CFR 1910.1020), PPE requirements, and the General Duty Clause (OSHA — TB Standards).

Two things trip people up:

Recordability on the OSHA 300 Log. Under 29 CFR 1904.11, you record a work-related TB case as a respiratory condition when an employee is occupationally exposed to someone with a known case of active TB and then develops TB infection — shown by a skin-test conversion or a clinician's diagnosis. Critically, a positive test found at the preplacement/baseline physical is NOT recordable, because there was no occupational exposure in your workplace. And if a logged case is later shown to have been acquired away from work, you may line it out.

Records retention. Under 29 CFR 1910.1020, employee medical records are kept for the duration of employment plus 30 years, and exposure records for at least 30 years. TB screening records fall squarely in scope — plan storage accordingly.

Respirators. When N95 or higher protection is needed for TB, it has to sit inside a full respiratory protection program: medical evaluation, training, and fit testing (OSHA — TB Control and Prevention).

Tracking all of this — baseline results, who has untreated LTBI (and therefore needs the annual symptom check), education completion, exposure-triggered testing, and 30-plus-year retention — is the ongoing operational work behind the guidance. Whatever system you use, the untreated-LTBI subset is the one that most often falls through the cracks, so build the reminder for it deliberately.

FAQ

Do we have to test every new hire? Yes. Baseline screening still applies to all healthcare personnel: risk assessment, symptom evaluation, and an IGRA or TST for anyone without a documented prior TB history (MMWR 2019).

Can we drop annual TB testing entirely? CDC no longer recommends routine annual testing, but check your state TB control program and any accreditation requirements first — CDC says "not routinely recommended," not banned, and local rules can require more.

Which is better, IGRA or TST? Neither is universally superior. IGRA is a single blood draw unaffected by prior BCG vaccination, making it strong for BCG-vaccinated staff and hard-to-reach workers; TST is lower-cost but needs two visits and can false-positive after BCG (CDC MMWR RR-5).

Is a positive baseline test recordable on the OSHA 300 Log? No. A positive test at a preplacement physical isn't recordable because there was no occupational exposure. Recordability applies only to a work-related conversion after exposure to a known active case (29 CFR 1904.11).

If your TB policy still reads like it was written in 2005, this is a good quarter to update it — retire the routine annual test, stand up annual education, flag your untreated-LTBI employees for symptom screening, and confirm your state's rules before you finalize. And whatever cadence you land on, make sure the records survive the 30-year retention clock. If you'd like to see how carefoundryESC handles TB screening records and reminders, reach out for a walkthrough.